Gilead Sciences (NasdaqGS:GILD) recently experienced a significant price movement, rising 24% in the last quarter. This ...

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...

Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.

New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...

The drug, which works by blocking HIV from entering and multiplying in human cells, remained in the body for at least 56 ...

Gilead Sciences hits a 52-week high buoyed by investor optimism. We believe there is still room for growth and recommend the ...

Sciences presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of ...

Yearly lenacapavir injection for HIV prevention shows safety and long-lasting effects, according to clinical trial results.

A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV ...